In pursuit of our policy to meet the strict requirements of the pharmaceutical industry as well as to achieve compliance with a host of different international standards, we can officially confirm the register of our DMF (Drug Master File) Nr.º 30288 with the U.S.A. Food and Drug Administration (FDA).

With the registration of our DMF, Ilhaplast has extended its competency framework and we are now entitled to participate in more ample projects or partnerships. Consequently, we are also empowered to issue letters of authorization (LOAs) so long as the firm is requested to consult the DMF with the U.S. FDA.

Guided by a policy of continuous improvement, we are working on other actions directed at broadening our offering as well as our compliance with the most recognized international standards, particularly those that allow us to improve and streamline processes at the level of industrial management. The principles of "lean manufacturing" are a concept we already follow!